CTI BioPharma Q3 Loss Widens

(RTTNews) - CTI BioPharma Corp. (CTIC) reported that its net loss attributable to common stockholders for the third quarter of 2018 was $14.8 million, or $0.26 per share, compared to a loss of $12.0 million, or $0.28 per share last year.

Total revenues for the third quarter were $0.7 million compared to $1.7 million last year. The decrease in total revenues for the third quarter in 2018 compared to the same period in 2017 is primarily due to the recognition of license and contract revenue in 2017 related to the achievement of a regulatory milestone under the license and collaboration agreement for PIXUVRI® with Servier.